Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Launching "6 vs 12" Campaign On Follow-On Biologics

This article was originally published in The Pink Sheet Daily

Executive Summary

Six-video series will profile patients struggling to pay for biologics in effort to make the case for brand exclusivity shorter than 12 years.

You may also be interested in...



Australia Questions Soliris Survival Benefit; Adds Listings From MSD, Novartis, Janssen To PBS

PERTH, Australia - Australia's Minister of Health Nicola Roxon requested advice from the Pharmaceutical Benefits Advisory Committee on the potential benefits of adding Alexion's Soliris (eculizumab) to the government's Life Saving Drugs Program (LSDP)

Follow-On Biologics: Defeat For Waxman, Win For Health Reform

Lopsided committee vote suggests that lengthy exclusivity is here to stay, which means that big pharma can get more comfortably behind the broader reform effort.

Obama Offers Specifics On Final Vote Timing, Follow-On Biologics

At a public town hall meeting in North Carolina, the President suggests late fall, lower exclusivity will feature in the conclusion of the health care debate.

Related Content

Topics

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel